Rhea-AI Summary
enGene Therapeutics (Nasdaq: ENGN) will change its corporate name to enGene Therapeutics Inc. effective April 8, 2026.
The company said it plans a BLA submission for detalimogene in 2H 2026 and is targeting a potential approval in 2027, while the LEGEND trial continues including a pivotal BCG‑unresponsive NMIBC with CIS cohort.
Trading symbols remain ENGN and ENGNW; new CUSIPs and ISINs for shares and warrants will take effect on the name change.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
FAQ
What is the current stock price of enGene Therapeutics Warrants (ENGNW)?
enGene Therapeutics Warrants (ENGNW) last closed at $0.17.